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In fasted rodents hepatic carnitine concentration increases considerably which is not observed in PPARα−/− mice, indicating that PPARα is
involved in carnitine homeostasis. To investigate the mechanisms underlying the PPARα-dependent hepatic carnitine accumulation we measured
carnitine biosynthesis enzyme activities, levels of carnitine biosynthesis intermediates, acyl-carnitines and OCTN2 mRNA levels in tissues of
untreated, fasted or Wy-14643-treated wild type and PPARα−/− mice. Here we show that both enhancement of carnitine biosynthesis (due to
increased γ-butyrobetaine dioxygenase activity), extra-hepatic γ-butyrobetaine synthesis and increased hepatic carnitine import (OCTN2
expression) contributes to the increased hepatic carnitine levels after fasting and that these processes are PPARα-dependent.
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Peroxisome Proliferator Activated Receptor α (PPARα) is a
ligand-dependent transcription factor. Upon ligand binding,
PPARα heterodimerizes with the Retinoid X Receptor and
binds to specific response elements (PPARα response elements,
PPREs) to stimulate expression of target genes. PPARα is
expressed in tissues with a high rate of fatty acid oxidation (such
as liver, heart, skeletal muscle, kidney and brown adipose
tissue) [1] and several aspects of fatty acid metabolism are
regulated by PPARα, including the cellular uptake of fatty
acids, the activation of fatty acids, peroxisomal and mitochon-Abbreviations: PPARα, Peroxisome proliferator activated receptor α; TML,
6-N-trimethyllysine; TMLD, 6-N-trimethyllysine dioxygenase; HTML, 3-
hydroxy-6-N-trimethyllysine; TMABA, 4-trimethylaminobutyraldehyde;
TMABA-DH, 4-trimethylaminobutyraldehyde dehydrogenase; γ-BB, 4-tri-
methylaminobutyric acid; γ-BBD, 4-trimethylaminobutyric acid dioxygenase
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doi:10.1016/j.bbabio.2007.07.001drial β-oxidation, ketogenesis, ω-oxidation and lipoprotein
metabolism [1–6].
Several observations suggest that PPARα is involved in
carnitine homeostasis. Carnitine is an essential compound in
fatty acid metabolism due to its role in the transfer of long-chain
fatty acids into the mitochondrial matrix, where β-oxidation
takes place [7,8]. Carnitine is also used to transport peroxisomal
β-oxidation products to the mitochondria, to export accumu-
lating acyl-groups and to modulate the level of free CoA in
different subcellular compartments [9,10].
Carnitine can be absorbed from the diet and synthesized
endogenously [10]. OCTN2 (SLC22A5) is the sodium-dependent
carnitine transporter responsible for the dietary absorption of
carnitine. This transporter also mediates cellular uptake and renal
reabsorption of both carnitine and its precursor, 4-trimethylami-
nobutyric acid (γ-butyrobetaine, γ-BB) (Fig. 1) [10,11]. The first
metabolite of the carnitine biosynthesis pathway (Fig. 1) is 6-N-
trimethyllysine (TML), which is generated by lysosomal
degradation of proteins containing trimethylated lysine residues
(such as calmodulin, histones, actin and myosin). Free TML is
hydroxylated by the enzyme TML-dioxygenase (EC 1.14.11.8,
TMLD) to 3-hydroxy-6-N-trimethyllysine (HTML). HTML is
Fig. 1. Cellular import and biosynthesis of carnitine: TML (6-N-trimethyllysine) is hydroxylated by TMLD (TML-dioxygenase) to HTML (3-hydroxy-6-N-
trimethyllysine), which is converted to TMABA (4-trimethylaminobutyraldehyde) by HTML-aldolase. TMABA-DH (TMABA-dehydrogenase) oxidizes TMABA to
γ-BB (4-trimethylaminobutyric acid), which is hydroxylated to carnitine by γ-BBD (γ-BB dioxygenase). OCTN2 imports carnitine and its precursor, γ-BB [10].
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(TMABA), which is oxidized by TMABA-dehydrogenase (EC
1.2.1.47, TMABA-DH) to γ-BB. Finally, γ-BB is hydroxylated
to carnitine by γ-BB dioxygenase (EC 1.14.11.1, γ-BBD), which
in mice is only present in liver [12], (Fig. 1) [10,13,14].
In both rat and mouse, treatment with PPARα agonists has
been shown to influence liver carnitine metabolism [5,15]. Upon
treatment, hepatic carnitine concentration increased consider-
ably in two independent studies [5,15]. Based on experiments
with clofibrate-fed rats (a synthetic PPARα ligand) Paul et al.
proposed that the increase was due to an increase in the rate of
hepatic carnitine synthesis [15]. More recently, however, we
could not demonstrate increased activity of carnitine biosynthe-
sis enzymes in phytol-treated mice (phytanic acid and its
precursor phytol, are natural PPARα ligands [16,17]), despite an
obvious increase in hepatic carnitine concentration [5]. When
mice or rats are fasted, which also results in PPARα activation,
liver carnitine levels also rise considerably [6,18]. This is not
observed in fasted or PPARα agonist-fed PPARα−/− mice,
indicating that this effect is mediated via PPARα [5,6].
To investigate the role of PPARα in carnitine metabolism and
determine what mechanism underlies the hepatic increase of
carnitine concentration we used wild type and PPARα−/− mice
which were either fed normal chow, chow containing the potent
PPARα agonist Wy-14643 [1] or were fasted for 48 h. We
measured carnitine biosynthesis enzyme activities, levels ofcarnitine biosynthesis intermediates, acylcarnitines and OCTN2
mRNA levels in selected tissues and compared the data from
the different treatment groups. Our results show that both
enhanced carnitine biosynthesis and differential OCTN2 expres-
sion contribute to the PPARα-dependent changes in carnitine
metabolism.
2. Materials and methods
2.1. Chemicals
RNAlater reagent was obtained from Qiagen, the Trizol reagent from
Invitrogen, The first-strand cDNA synthesis kit and the LightCycler FastStart
DNAMaster SYBR Green I kit from Roche and Wy-14643 was purchased from
Tocris Bioscience.
2.2. Animals
Control diet was produced by soaking pelleted mouse chow (CRM(pl),
Technilab SDS) in ethanol (33 ml ethanol per 100 g pellets) and the pellets were
left to dry. For the 0.1% (w/w) Wy-14643-diet, 100 g pellets were soaked in
33 ml ethanol containing 3 mg/ml (e.g. 100 mg) Wy-14643. Subsequently, the
pellets were left to dry.
All mice were obtained from the Jackson Laboratory. Male 129 wild type
and PPARα−/− mice were fed normal mouse chow until 9 weeks of age. Next,
mice were divided into three groups. The first group (wild type n=5 and
PPARα−/− n=5) was fed control food for 2 weeks at libitum. The second group
(wild type n=5 and PPARα−/− n=5) received chow supplemented with 0.1%
Wy-14643 for 2 weeks at libitum. The last group (wild type n=5 and PPARα−/−
Fig. 2. Western blot analysis of peroxisomal straight-chain acyl-CoA oxidase in livers of 3 wild type and 3 PPARα−/−mice on control diet, onWy-14643-diet or fasted
for 48 h. Band intensities were quantified using ImageJ sofware (http://rsb.info.nih.gov/ij/index.html) [21]. Values are means±standard deviation of three mice.
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mice had free access to water and were killed at the same time of day. At the
end of the experiment, mice were anesthetized with isoflurane and blood wasFig. 3. Carnitine levels in plasma and different tissues of wild type (+/+) and PPARα
means±standard deviation. a indicates a significant difference ( pb0.05) between mic
significant difference ( pb0.05) between mice with a different genotype but the sam
treated mice and fasted mice with the same genotype.collected by cardiac puncture. Tissues (liver, heart, kidney and gastrocnemius
muscle) were collected and a small piece was treated with RNAlater reagent
according to the manufacturer's instructions and stored at −80 °C until RNA−/− mice (−/−) on control diet, on Wy-14643-diet or fasted for 48 h. Values are
e with the same genotype on the control diet and another treatment. b indicates a
e treatment. c indicates a significant difference ( pb0.05) between Wy-14643-
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−80 °C until further use. All experiments were approved by the local ethical
committee.
2.3. Carnitine metabolites and biosynthesis enzymes
Levels of carnitine biosynthesis intermediates, acyl-carnitines and
activities of carnitine biosynthesis enzymes were determined as described
previously [12,19]. In short, carnitine biosynthesis intermediates and acyl-
carnitines were extracted from lyophillized tissue pieces using acetonitrile. The
extracted acyl-carnitines were derivatized with a 4:1 mixture of propanol and
acetylchloride and analyzed with tandem-MS. The extracted biosynthesis
intermediates were derivatized with methylchloroformiate and analyzed with
tandem-MS [20]. To determine the activities of the carnitine biosynthesis
enzymes, tissue homogenates were incubated with the appropriate substrates
and co-factors. After incubation the samples were deproteinized and
derivatized with methylchloroformiate. Product formation was analyzed with
tandem-MS [12].
2.4. Immunoblot analysis
Immunoblot analysis of peroxisomal straight-chain acyl-CoA oxidase was
performed as described previously [5]. The bands were quantified using the
ImageJ sofware (http://rsb.info.nih.gov/ij/index.html) [21].
2.5. Quantitative real-time RT-PCR analysis
Total RNA was isolated from RNAlater-treated tissues using Trizol
extraction. cDNA was produced using a first-strand cDNA synthesis kit. For
the quantitative real-time PCR the LightCycler FastStart DNA Master SYBR
Green I kit was used and the following primers: 5′GTGGGCCGCTCTAGG-
CACCAA3′ and 5′CTCTTTGATGTCACGCACGATTTC3′ for β-actin [22], 5′
ACCCCACTGTGGTCAGAAAC3′ and 5′CACCAAAGCTCTCAGG-
GAAG3′ for OCTN2 and 5′CACCTGGGGTTCAGCTTCTG3′ and 5′
CACATCACCTGGATTCATCTTG3′ for γ-BBD. All samples were analyzed
in duplicate. To confirm that a single product was formed during PCR, melting
curve analysis and agarose gel electrophoresis were performed. The data were
analyzed using linear regression calculations as described previously [23] and
values for OCTN2 and γ-BBDmRNA levels were normalized against the values
for the housekeeping gene β-actin to adjust for variations in the amount of input
RNA.
2.6. Statistical analyses
Data are expressed as means±standard deviation. Statistical significance
was evaluated using an unpaired Student's t-test. The results were considered
significant at p≤0.05.Table 1
Activity of carnitine biosynthesis enzymes in tissues of wild type and PPARα−/− m
Wild type mice
Control diet Wy-14643 diet F
Liver TMLD 21.7±6.9 19.4±5.3 1
TMABA-DH 4654±712 5137±981 4
γ-BBD 141±17 208±19 a
Kidney TMLD 45.1±6.0 52.2±8.0 4
TMABA-DH 2241±314 3753±93 a 2
Heart TMLD 30.5±5.5 18.1±6.0 a 2
TMABA-DH 189±87 225±86
Muscle TMLD 3.6±2.1 3.6±1.1
TMABA-DH 102±61 64±13
All activities are given in pmol×min−1×mg protein−1. Values are means±standard
a With significant difference ( pb0.05) between mice with the same genotype on
b With significant difference ( pb0.05) between mice with a different genotype b
c With significant difference ( pb0.05) between Wy-14643-treated mice and faste3. Results
3.1. Mice
At the age of 9 weeks, there was no significant difference
in body weight between wild type and PPARα−/− mice (21.3±
1.9 g and 24.2±3.3 g). Also, after the diet period both groups
had similar body weights (22.3±1.5 g and 25.8±3.5 g).
After the 48-h fasting period wild type and PPARα−/−mice lost
4.6±0.5 g, which was approximately 17% of their total body
weight.
3.2. Activation of PPARα
In order to confirm activation of PPARα and enhanced
expression of its target genes by the 0.1% Wy-14643 diet and
the 48-h fasting period, we used immunoblot analysis of
peroxisomal straight-chain acyl-CoA oxidase, a known PPARα
target. Compared to wild type mice on the control diet, straight-
chain acyl-CoA oxidase was much more abundant in livers of
fasted wild type mice and wild type mice on the Wy-14643-diet
(Fig. 2), demonstrating that both treatment protocols activate
PPARα and induce expression of this target gene. As expected,
the Wy-14643-diet had no effect in PPARα−/− mice. Fasting
does appear to increase the quantity of straight-chain acyl-CoA
oxidase in PPARα−/− mice, indicating that the abundance of
this protein is also regulated in a PPARα-independent manner.
This effect has been observed previously [5].
3.3. Carnitine levels
Measurement of plasma and tissue carnitine levels showed
that they differ profoundly between wild type and PPARα−/−
mice and between the different treatment groups (Fig. 3).
Because the differences in free carnitine levels between the
groups were very similar when compared to the differences
observed in total carnitine levels, we only show results for free
carnitine. This also implies that the degree of acylation is not
different, which was confirmed by analysis of the acyl-carnitine
spectra (results not shown).ice
PPARα−/− mice
asting Control diet Wy-14643 diet Fasting
9.0±3.4 37.4±8.7 b 37.7±4.2 b 40.0±7.2 b
015±587 4218±368 4340±608 3259±271 a, c
269±34 a, c 151±21 177±14 b 148±19 b
3.5±7.2 44.0±6.0 51.2±15.8 52.0±17.7
838±120 a, c 1632±167 b 1732±189 b 2109±315 a, b
1.2±4.4 a 33.9±3.3 34.9±5.5 b 33.0±4.6 b
166±20 250±70 207±48 156±31 a
1.8±0.3 c 0.6±0.4 b 0.9±0.7 b 1.4±1.2
36±18 ND ND ND
deviation. ND=not detectable.
the control diet and another treatment.
ut the same treatment.
d mice with the same genotype.
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carnitine levels betweenwild type andPPARα−/−mice. Compared
to wild type mice, PPARα−/− mice had lower plasma carnitine
concentration (16±4 μM vs. 30±4 μM) and lower carnitine levels
in all investigated tissues (Fig. 3).
When wild type mice were fed Wy-14643, the carnitine levels
in plasma, liver, kidney, and heart rose significantly when
compared to mice fed the control diet (Fig. 3). In fasted wild type
mice, only the hepatic carnitine level was elevated (1.5-fold)
compared to mice on the control diet. In these animals, plasma
carnitine level was decreased when compared to fed mice.
Neither the Wy-14643-diet nor fasting led to an elevation of
plasma or tissue carnitine levels in PPARα−/− mice (Fig. 3).Fig. 4. TML (open bars) and γ-BB (filled bars) levels in plasma and different tissues o
fasted for 48 h. Values are means±standard deviation. a indicates a significant diffe
another treatment. b indicates a significant difference ( pb0.05) between mice with
( pb0.05) between Wy-14643-treated mice and fasted mice with the same genotype3.4. Carnitine biosynthesis enzymes and intermediates
In order to determine if the observed differences in carnitine
levels resulted from differences in carnitine biosynthesis we
measured the activities of carnitine biosynthesis enzymes (Table 1)
and the levels of biosynthesis intermediates (Fig. 4).
The lower carnitine levels observed in the tissues and plasma
of PPARα−/− mice on the control diet, compared to wild type
mice on control diet, were probably not due to diminished
carnitine biosynthesis, since the carnitine biosynthesis enzyme
activities and the levels of carnitine biosynthesis intermediates are
similar in both groups. The activity of the different enzymes
involved in carnitine biosynthesis only was lower in skeletalf wild type (+/+) and PPARα−/− (−/−) mice on control diet, onWy-14643-diet or
rence ( pb0.05) between mice with the same genotype on the control diet and
a different genotype but the same treatment. c indicates a significant difference
.
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muscle, however, the γ-BB production probably is minimal even
in wild type mice, given the very low TMLD and TMABA-DH
activity in this tissue. TMABA-DH activity is always much
higher than the TMLD activity, which suggests that the lower
TMABA-DH activity observed in PPARα−/− kidney probably
has no effect on γ-BB production in this tissue. This is supported
by the fact that the γ-BB levels in muscle and kidney do not differ
significantly between wild type and PPARα−/−mice (Fig. 4). As
shown previously [12], HTML is not detectable in any of the
investigated mouse tissues and plasma.
The increase in plasma and tissue carnitine levels after Wy-
14643 treatment of wild type mice is accompanied by a decrease
of γ-BB levels in all tissues and plasma compared to the control
diet (Fig. 4). This is most likely caused by enhanced conversion of
γ-BB into carnitine, because there is a significant increase in liver
γ-BBD activity after the Wy-14643-diet (208±19 vs. 141±17
pmol×min−1×mg−1, Table 1). The lower γ-BB levels in theWy-Fig. 5. (A) Alignment of DR1 sequences (underlined) of the mouse, rat and human B
sequence are printed in italics. (B) γ-BBD mRNA levels in livers of wild type (+/+)
(C) OCTN2 mRNA levels in livers of wild type (+/+) and PPARα−/− (−/−) mice on
hearts of wild type (+/+) and PPARα−/− (−/−) mice on control diet. Values are means
with the same genotype on the control diet and another treatment. b indicates a signif
treatment. c indicates a significant difference (pb0.05) between Wy-14643-treated m14643 group were probably not caused by a decrease in γ-BB
synthesis, because TML levels (Fig. 4) and TMLD activity
(Table 1) were similar to those of the control group in all tissues
except heart, which showed a lower TMLD activity. Tissue
TMABA-DHactivitywas similar in both groups except in kidney,
where a higher TMABA-DH was measured after the Wy-14643-
diet.
When wild type mice were fasted, the hepatic γ-BBD activity
almost doubled, compared to fed mice (Table 1), most likely
resulting in enhanced carnitine production. This was supported
by the fact that γ-BB levels were decreased in plasma, liver and
kidney of fasted mice (Fig. 4), whereas γ-BB synthesis did
not appear to be reduced given the normal plasma, kidney and
liver TML levels (Fig. 4) and TMLD / TMABA-DH activity
(Table 1).
Like the carnitine levels, carnitine biosynthesis enzyme
activities and biosynthesis intermediate levels were not altered by
either the Wy-14643 treatment or fasting in the PPARα−/− mice.BOX1 genes. The four nucleotides which are different from the consensus PPRE
and PPARα−/− (−/−) mice on control diet, on Wy-14643-diet or fasted for 48 h.
control diet, on Wy-14643-diet or fasted for 48 h. (D) OCTN2 mRNA levels in
±standard deviation. a indicates a significant difference (pb0.05) between mice
icant difference ( pb0.05) between mice with a different genotype but the same
ice and fasted mice with the same genotype.
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Because of the apparent PPARα-dependent increase inγ-BBD
activity, we examined the promotor of the γ-BBDgene (bbox1) of
mouse, rat and man for PPREs and measured the mRNA levels of
γ-BBD in liver. Using theNUBIScan software [24]we analyzed a
1000-bp sequence upstream of the ATG of the BBOX1 gene from
mouse, rat and man.We found three conserved DR1 sequences in
all three species located approximately 110 bp upstream of the
start-codon. Fig. 5A shows an alignment of the region containing
the DR1 sequences. The NUBIScan score and p-value for all
three analyses were 0.81647 (with a maximum of 1.0) and
b0.002, respectively.
We also determined the hepatic γ-BBD mRNA levels in the
different groups using quantitative PCR. The γ-BBD mRNA
levels are lower in the PPARα−/− mouse when compared to
wild type (Fig. 5B). Fasting induces the expression of γ-BBD in
the wild type mice but not in PPARα−/− mice. Surprisingly, no
enhanced expression is observed in Wy-14643-treated wild type
mice.
Apart from the rate of carnitine biosynthesis, carnitine levels
can also be influenced by alterations in carnitine transport. To
investigate this, we determined OCTN2 mRNA levels in various
tissues by quantitative PCR. In liver and heart, PPARα−/− mice
had considerably lower levels of OCTN2 mRNA (5-fold and 3.5-
fold, respectively) compared to the wild type mice (Fig. 5C). This
could contribute to the lower carnitine levels observed in these
tissues of PPARα−/−mice. Surprisingly, no significant difference
in kidney or skeletal muscle OCTN2 expression was found
between wild type and PPARα−/− mice (results not shown).
In the wild typemice both theWy-14643 diet and fasting led to
an significant increase in hepatic OCTN2 expression (Fig. 5C).
This most likely contributes directly to the increased hepatic
carnitine level, but also indirectly given that OCTN2 also
transports γ-BB, which (via the elevated γ-BBD activity) also
yields carnitine. Surprisingly, OCTN2 expression was unchanged
in kidney, heart and skeletal muscle after fasting or Wy-14643
treatment (results not shown). Unfortunately, neither urine nor
intestine was collected, so we cannot exclude the possibility that
renal carnitine reabsorption or increased intestinal carnitine
uptake also contributes to the increased carnitine levels. However,
because the kidney OCTN2 mRNA levels (the main transport
system for carnitine reabsorption) were unchanged, compared to
the control diet, it is unlikely that there is enhanced renal
reabsorption of carnitine contributing to the higher tissue carnitine
levels.
As expected, the Wy-14643-diet had no effect in PPARα−/−
mice. Hepatic OCTN2mRNA levels, however, did increase upon
fasting, when compared to fed PPARα−/− mice (Fig. 5C).
Nevertheless, expression of OCTN2 in the liver of fasting
PPARα−/−mice was still lower (∼2-fold) than in wild type mice
on control diet and therefore probably too low to increase the liver
carnitine concentration.
In contrast to the apparent PPARα-dependency of OCTN2,
NUBIScan analysis of the OCTN2 promotor (1000 bp up-
stream of the start-codon) did not reveal a DR1 sequence with a
low p-value.4. Discussion
Fasting or treatment with PPARα agonists increases the
carnitine concentration in liver. The reason for this increase in
hepatic carnitine content is still a matter of speculation, however,
it seems logical to increase the liver carnitine levels during fasting
when β-oxidation is enhanced, since carnitine is an important
buffer of acyl-groups and thereby ensures that there is enough free
CoA to sustain the high metabolic flux.
We have shown that in fasted and Wy-14643-fed wild type
mice the elevation of the liver carnitine level is caused by an
enhancement of both hepatic carnitine and γ-BB uptake
(OCTN2 expression) and biosynthesis (primarily by increasing
γ-BBD activity). In PPARα−/− mice, neither the Wy-14643-
treatment nor fasting led to an elevation of the hepatic carnitine
concentration or enhancement of the liver γ-BBD activity or
mRNA levels. These results indicate that γ-BBD activity is
regulated by PPARα. In contrast, hepatic γ-BBD mRNA levels
of wild type mice were not elevated by 2 weeks of Wy-14643
treatment. This discrepancy has also been observed for short-
chain hydroxyl-acyl-CoA dehydrogenase [2], where 2 weeks of
Wy-14643 treatment resulted in a clear induction of short-chain
hydroxyl-acyl-CoA dehydrogenase protein but not in elevation
of the mRNA levels. The observed differences between γ-BBD
activity and mRNA levels could result from the relatively long
period of Wy-14643 treatment (2 weeks). Wy-14643 treatment
for 6 h or 5 days did result in an increase in γ-BBD mRNA
levels (1.95-fold and 1.7-fold, respectively) as was shown in
recent experiments (data available at http://nutrigene.4t.com/
microarray/ppar2007/, Kersten, S., personal communication). It
is possible that after an initial stimulation of γ-BBD expression
by PPARα the mRNA levels slowly return to normal while the
protein levels remain elevated. γ-BBD activity, however, does
not appear to correspond with its mRNA levels. γ-BBD activity
is similar in livers of both wild type and PPARα−/−mice on the
control diet, but mRNA levels are much lower in the PPARα−/−
mice compared to wild type animals. The presence of a putative
PPRE in the promoter of the bbox1 gene supports the role of
PPARα in the regulation of γ-BBD. Although 4 nucleotides in
this DR1 sequence differ from the consensus PPRE sequence,
the fact that this sequence is conserved between mouse, rat and
man and that these alternative nucleotides are also found in
PPRE sequences of other genes indicates that this sequence is
likely to act as a functional PPRE. Further investigations are
needed to confirm this.
Previously, we did not observe higherγ-BBD activity in phytol
treated mice [5], despite a clear elevation of the liver carnitine
content. Although we did not measure OCTN2 mRNA levels in
these mice, it is very likely that enhanced hepatic carnitine uptake
was the cause of the increased liver carnitine concentration after
the phytol diet. Because phytol metabolites are much weaker
PPARα agonists than Wy-14643, a difference in PPARα
sensitivity between OCTN2 and γ-BBD might explain the fact
that we did not find increasedγ-BBDactivity in our phytol-treated
mice. This is supported by recent experiments (data available at
http://nutrigene.4t.com/microarray/ppar2007/, Kersten, S., per-
sonal communication), where Wy-14643 treatment for 5 days
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in a 1.7-fold increase inγ-BBDmRNA levels. OCTN2 appears to
be more sensitive to stimulation by PPARα than γ-BBD.
Fasting (but not Wy-14643-treatment) did lead to a relatively
large increase (3-fold) in liver OCTN2 expression in PPARα−/−
mice, although OCTN2 mRNA levels only increased to half of
wild type levels on control diet. This indicates that OCTN2
expression is regulated both by a PPARα-dependent and in-
dependent mechanism. In fed rats (where levels of endogenous
PPARα ligands are low) treatment with glucagon or anti-insulin
serum (which mimics the levels of these hormones during
fasting) led to an increase in liver carnitine [18]. Although this
experiment does not differentiate between elevation of the
carnitine concentration by biosynthesis or by hepatic carnitine
uptake, these results together with the observed increase in
OCTN2 expression in the fasted PPARα−/− mice suggest that
liver OCTN2 levels could be influenced by high glucagon or
low insulin levels. More studies are needed to investigate
whether this relation indeed exists.
While γ-BBD and OCTN2 are upregulated by PPARα
activation, TMLD activity in wild type mice was not altered by
Wy-14643-treatment, except in heart (Table 1). In this tissue
TMLD activity was decreased in both fasted and Wy-14643-fed
wild type mice when compared to the control diet (Table 1).
This was not observed in the PPARα−/− mice, indicating that
the reduction in heart TMLD activity is PPARα-dependent. In
contrast, liver TMLD activity is not altered by Wy-14643-
treatment or fasting in both wild type and PPARα−/− mice
(Table 1). PPARα−/− mice, however, have an almost 2-fold
higher basal TMLD activity as compared to wild type mice,
indicating that like in heart, TMLD activity is negatively
influenced by PPARα. Oddly, the opposite was observed in
skeletal muscle, where the TMLD activity in PPARα−/− mice
on control or on Wy-14643-diet was lower than in wild type
mice. Given these discrepancies, it seems that TMLD is not only
regulated by PPARα, but also by other factors.
Although Wy-14643-supplemented chow and fasting both
stimulate PPARα, these treatments have different effects on
carnitine homeostasis. Wy-14643 very specifically stimulates
PPARα, while during fasting carnitine metabolism is also
influenced by other factors. PPARα activation in fed Wy-14643
treated mice, however, does not reflect the physiological situation
in which PPARα is normally stimulated by endogenous ligands,
which are released upon fasting. The differences between these
treatments are apparent in Fig. 4. Heart and skeletal muscle TML
and γ-BB levels are elevated in fasted animals compared to Wy-
14643 treated mice (Fig. 4). These differences are PPARα-
independent because they are also observed in PPARα−/− mice.
TML originates from protein breakdown [13,25], and for this
reason the increase in TML levels most likely reflects fasting-
induced proteolysis. The elevated levels of TML indirectly, via
extra-hepatic conversion to γ-BB, provide the liver with ad-
ditional carnitine precursors. In heart, the higher TML levels are
accompanied by an increase in γ-BB, but this is not observed in
skeletal muscle (Fig. 4). This could be explained by the very low
muscle TMLD activity and the almost complete absence of
TMABA-DH activity (Table 1).InWy-14643-treated wild typemice, plasma, liver, kidney and
heart carnitine levels were higher when compared to fasted wild
type mice (Fig. 3). Since there was no significant difference in
carnitine acylation (results not shown) or carnitine biosynthesis
enzyme activities between these two groups, the difference in free
carnitine level is probably due to the difference in length of the
treatment. Mice were treated with Wy-14643 for 2 weeks but
fasted for “only” 48 h. In both situations carnitine synthesis was
enhanced, γ-BBD activity after fasting was even more increased
than after Wy-14643-treatment (Table 1), but Wy-14643-treated
mice had more time to accumulate carnitine than fasted mice.
Possibly, carnitine first accumulates in the liver and later, after a
prolonged period of carnitine synthesis, also in other tissues. This
may result in the observed low plasma carnitine level of fasted
wild type mice and the elevated plasma carnitine level in Wy-
14643 treated wild type mice. We cannot exclude, however, that
differences in urinary carnitine excretion contribute to the
observed carnitine levels.
During preparation of this manuscript Luci et al. reported
that OCTN2 expression is increased in the liver of clofibrate-fed
rats [26]. The authors did not find an increase in mRNA levels
coding for carnitine biosynthesis enzymes after PPARα agonist
treatment. Based on this observation and the fact that TML
levels in medium of rat hepatoma cells did not decrease upon
Wy-14643 treatment, they concluded that the PPARα-depen-
dent increase in liver carnitine levels was solely mediated by
enhanced OCTN2 expression and not by enhanced carnitine
biosynthesis. This is in contrast to our results with Wy-14643-
treated and fasted wild type mice, where an increase in both γ-
BBD activity (and γ-BBD mRNA levels after fasting) and
OCTN2 expression was found, which both contribute to
elevated carnitine levels. These differences could be the result
of the difference in species (mice vs. rats) or that 4 days of
clofibrate treatment is less effective in stimulating PPARα target
genes than Wy-14643 (a 5-day treatment of Wy-14643 does
result in upregulation of γ-BBD mRNA).
Although the studies of Luci et al. are well designed, the
authors forgot to take into account several aspects of carnitine
homeostasis. Firstly, γ-BB is an excellent substrate for OCTN2
[11]. For this reason, upregulation of this transporter also
enhances the delivery of carnitine equivalents to the liver and
given the very large capacity of the liver to convert γ-BB into
carnitine [27], the upregulation of OCTN2 enhances the flux
through the carnitine biosynthesis pathway. Secondly, TML is
poorly absorbed by the liver [28]. The kidney converts most of
the circulatory TML into γ-BB, which is subsequently imported
into the liver and converted into carnitine [29]. The fact that
TML levels in medium of rat hepatoma cells remain the same
after Wy-14643 treatment [26] does not disprove that the
increase of the carnitine concentration in livers of rodents
treated with PPARα agonists is caused by an increased hepatic
carnitine synthesis. In general, experiments in cell culture
systems are not suited to draw conclusions concerning whole
organism metabolism.
In conclusion, we show that the observed increase in liver
carnitine levels upon fasting or PPARα agonist treatment is
mediated by a PPARα-dependent increase in hepatic transport
1142 N. van Vlies et al. / Biochimica et Biophysica Acta 1767 (2007) 1134–1142of both carnitine and its precursor γ-butyrobetaine, as well as
enhanced systemic carnitine biosynthesis.
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